Sources: Huawei plans hundreds of layoffs at Futurewei Technologies, its US R&D subsidiary, which employs about 850 people in research labs across the US
Cuts are expected to affect workers at U.S.-based R&D subsidiary Futurewei Technologies — Huawei Technologies Co …
Context & Ripple Effects
This is the endgame of a squeeze that built all year: in January the Commerce Department signaled it would not renew the export license for Futurewei's Silicon Valley labs (refusing to renew Futurewei's export license), and by late June the unit had moved to separate its operations from its parent while staying Huawei-owned (Futurewei splitting off its operations). With about 850 researchers on US payroll and no legal way to move work back across the corporate boundary, hundreds of job cuts were the arithmetic next step.
It also rhymes with an older playbook — Huawei cut its entire US employee base in 2018 when political outreach stalled (Huawei's 2018 pullback from US staff) — so this is less a one-off than the second contraction of Huawei's American footprint in two years, this time forced by the trade blacklist rather than market rejection.
First-order effects
- Hundreds of Futurewei's roughly 850 US research staff lose their jobs or face transfer out of work tied to the parent company, gutting Huawei's onshore R&D capacity in areas like chips and networking where US talent mattered most.
Second-order effects
- Rivals with unrestricted US research footprints gain a hiring pool of experienced Huawei-trained engineers, and US universities and lab partners lose a major corporate funder of applied research.
Third-order effects
- If the blacklist logic holds, Chinese tech firms' US R&D arms become structurally untenable — a pattern echoed years later when Hikvision reportedly planned deep R&D cuts — pushing companies like Huawei to rebuild research inside China instead, which is exactly the domestic chip-rebuilding effort its scientists describe now.
The trend: US export controls are unwinding Chinese tech companies' American research presence, forcing R&D re-shoring to China and turning US labs into collateral damage of the tech decoupling.